TNF and metabolic dysfunction-associated steatotic liver disease: The findings highlight the significance of targeting oxidative stress pathways, such as reinstating SIRT1 activity or decreasing TNF-α, as prospective therapeutic approaches to alleviating fibrogenic development in MASLD.